Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with...
Sydney, Australia 8 October 2024 Highlights Clarity has entered into a 64Cu-SAR-bisPSMA Clinical Manufacturing Agreement for its Phase III clinical trials with SpectronRx. This Clinical Manufacturing...
View ArticleClarity promotes Michelle Parker to CEO
Sydney, Australia 14 October 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleClik here to view.
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in...
Sydney, Australia 14 October 2024 Highlights United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate...
View ArticleClik here to view.
Copper-67 SAR-bisPSMA updates
Sydney, Australia 16 October 2024 Highlights Cohort 4 – SECuRE Trial The third participant of cohort 4 (multi-dose) of the SECuRE trial1 has now completed the Dose Limiting Toxicity (DLT) period after...
View ArticleClik here to view.
CMS final rule on radio-diagnostic reimbursement policy, expanding patient...
Sydney, Australia 5 November 2024 Highlights The U.S. Centers for Medicare and Medicaid Services (CMS) has published its final rule for CY2025, which establishes a separate payment for high value...
View ArticleClarity and Nucleus RadioPharma sign Master Services Agreement and Cu-67...
Sydney, Australia 11 November 2024 Highlights Nucleus RadioPharma will manufacture the 67Cu-SAR-bisPSMA drug product at their new state-of-the-art facility in Rochester, MN. The Master Services...
View ArticleSt Vincent’s Hospital to conduct head-to-head trial with Clarity’s...
Sydney, Australia 18 November 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleClik here to view.
First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA trial
Sydney, Australia 26 November 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve...
View ArticleClik here to view.
Last patient assessment completed for diagnostic SARTATE trial in NETs
Sydney, Australia 28 November 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve...
View ArticleClik here to view.
Clarity expands its pipeline with a novel optimised FAP-targeted...
Sydney, Australia 18 December 2024 Highlights Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of...
View Article